Abhishek Shah, MD
Clinical Cardiac Electrophysiology · Chula Vista, CANPI 1972887073
Payments from drug & device makers
Across 512 payments — averaging $78.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medical Device Business Services, Inc.$10K
- Abbott$8K
- Boston Scientific$7K
- Medtronic$6K
- Biotronik Inc.$2K
- Biosense Webster, Inc.$2K
- plus $6K from 31 others
What the payments were for
- Consulting fees$9,75024%
- Grants$5,00012%
- Travel & lodging$5,88715%
- Food & beverage$19,09348%
- Education$4031%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medical Device Business Services, Inc. | 9 | $9,750 |
| Abbott | 167 | $7,866 |
| Boston Scientific | 91 | $7,407 |
| Medtronic(2 entities) | 16 | $6,260 |
| Biotronik Inc. | 14 | $1,588 |
| Biosense Webster, Inc. | 60 | $1,542 |
| Edwards Lifesciences | 8 | $1,193 |
| Cardiva Medical, Inc. | 44 | $1,040 |
| Heartflow, Inc. | 7 | $832 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 15 | $376 |
| Shockwave Medical, Inc | 2 | $319 |
| Pfizer | 16 | $291 |
| Impulse Dynamics (USA) Inc. | 2 | $251 |
| E.r. Squibb & Sons, L.L.C. | 12 | $230 |
| Johnson & Johnson | 4 | $169 |
| Novartis | 6 | $122 |
| Cleerly, Inc. | 1 | $83 |
| Alnylam Pharmaceuticals Inc. | 4 | $71 |
| Kestra Medical Technology Services, Inc. | 2 | $71 |
| Abiomed | 2 | $67 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $60 |
| Novo Nordisk | 2 | $56 |
| Cordis US CORP. | 3 | $52 |
| Cvrx, Inc. | 3 | $45 |
| Cardiofocus, Inc. | 1 | $44 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $42 |
| Bayer | 2 | $41 |
| Astellas Pharma US Inc | 2 | $40 |
| Philips North America LLC | 2 | $35 |
| AstraZeneca | 2 | $34 |
| Acutus Medical, Inc. | 1 | $30 |
| Amgen | 2 | $29 |
| Scpharmaceuticals Inc. | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $18 |
| Irhythm Technologies, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Carto 3$10,242
- GENERAL - THERAPIES$3,472
- AVEIR$2,166
- Ensite Cardiac Mapping System$849
- FFRct$735
- Arctic Front$583
- SAPIEN 3 Ultra RESILIA$574
- OPTIMIZER$503
- Confirm Rx$350
- Cardiva VASCADE MVP VVCS 6-12F$333
- Quadra Assura CRT Defibrillator$321
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$319
- Farapulse$299
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$280
- ENSITE$267
- RHYTHMVIEW$225
- ADVISOR$178
- RhythmVIEW Work Stations$174
- HeartMate 3 Left Ventricular Assist Device$137
- EMBLEM$127
How this compares
$40,133 in reported general payments places this provider in the 50th percentile of 290 clinical cardiac electrophysiology providers in California.
See all clinical cardiac electrophysiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 206 | $230,818 |
| XareltoRivaroxaban | 47 | $63,704 |
| FarxigaDapagliflozin Propanediol | 21 | $19,915 |
| Flecainide Acetate | 46 | $2,240 |
| Metoprolol Succinate | 135 | $2,178 |
| Amiodarone Hcl | 66 | $1,391 |
| Bumetanide | 14 | $1,300 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 15 | $711 |
| Amlodipine Besylate | 68 | $608 |
| Metoprolol Tartrate | 115 | $544 |
| Atorvastatin Calcium | 30 | $222 |
| Furosemide | 32 | $207 |
| Doxycycline Monohydrate | 26 | $143 |
| Carvedilol | 25 | $121 |
| Lisinopril | 22 | $95 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $291 | $230,818206 claims |
| Johnson & JohnsonXarelto | $169 | $63,70447 claims |
| AstraZenecaFarxiga | $34 | $19,91521 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 290 clinical cardiac electrophysiology providers in California.
Other clinical cardiac electrophysiology in Chula Vista
- David KrummenSan Diego$7.3M
- Jonathan DukesVentura$2.9M
- Shephal DoshiSanta Monica$2.9M
- Arash AryanaSacramento$2.4M
- Marco PerezStanford$2.1M
- Rahul DoshiLos Angeles$2M
- Mayer RashtianPasadena$1.8M
- Rajesh BankerNewport Beach$1.6M
- Edward GerstenfeldSan Francisco$1.5M
- Jonathan HsuSan Diego$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.